Active Shortage Injection Endocrinology/Metabolism
Liraglutide Injection · #30 of 35 active shortages by FDA posting duration
Brand: SAXENDA
FDA lists Liraglutide Injection as Active Shortage (Novo Nordisk, Inc.).
Availability on file: Available
Liraglutide Injection: Active Shortage
Available 9 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Liraglutide Injection
- Manufacturer
- Novo Nordisk, Inc.
- Dosage Form
- Injection
- Presentation
- Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)
- Package NDC
- 0169-2800-15
Status & Timeline
- Status
- Active Shortage
- Availability
- Available
- First Reported
- Jul 18, 2023
- Last Updated
- Mar 16, 2026
- Therapeutic Category
- Endocrinology/Metabolism
Row fields from the FDA Drug Shortages database via openFDA.
Full Drug Profile
liraglutide
Side effects, interactions, warnings & more
Nearby, Other Liraglutide Shortage Records
Liraglutide Injection
Meitheal Pharmaceuticals, Inc.
Injection
Liraglutide Injection
Meitheal Pharmaceuticals, Inc.
Injection
Liraglutide Injection
Novo Nordisk, Inc.
Injection
Liraglutide Injection
Novo Nordisk, Inc.
Injection
Liraglutide Injection
Novo Nordisk, Inc.
Injection
Liraglutide Injection
Novo Nordisk, Inc.
Injection